Tech Company Financing Transactions

Jounce Therapeutics Funding Round

Casdin Capital, Cormorant Asset Management and Foresite Capital participated in a $56 million Series B funding round for Jounce Therapeutics. This venture round closed on 4/23/2015.

Transaction Overview

Announced On
4/23/2015
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance Jounce's pipeline of cancer immunotherapy programs, including moving its lead program directed at Inducible T cell Co-stimulator (ICOS) into clinical testing, as well as advancing a second program through IND-enabling studies. In addition, the investment will support expanded discovery of novel treatments aimed at tumors that may be less likely to respond to T cell checkpoint monotherapy, including therapies that target innate immune and stromal cells.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
780 Memorial Dr.
Cambridge, MA 02138
USA
Email Address
Not Recorded
Overview
Jounce Therapeutics (NASDAQ: JNCE) is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
Profile
Jounce Therapeutics LinkedIn Company Profile
Social Media
Jounce Therapeutics Company Twitter Account
Company News
Jounce Therapeutics News
Facebook
Jounce Therapeutics on Facebook
YouTube
Jounce Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Richard Murray
  Richard Murray LinkedIn Profile  Richard Murray Twitter Account  Richard Murray News  Richard Murray on Facebook
Chief Financial Officer
Kim Drapkin
  Kim Drapkin LinkedIn Profile  Kim Drapkin Twitter Account  Kim Drapkin News  Kim Drapkin on Facebook
Chief Medical Officer
Elizabeth Trehu
  Elizabeth Trehu LinkedIn Profile  Elizabeth Trehu Twitter Account  Elizabeth Trehu News  Elizabeth Trehu on Facebook
Chief Technical Officer
Stephen Farrand
  Stephen Farrand LinkedIn Profile  Stephen Farrand Twitter Account  Stephen Farrand News  Stephen Farrand on Facebook
VP - Bus. Development
Hugh Cole
  Hugh Cole LinkedIn Profile  Hugh Cole Twitter Account  Hugh Cole News  Hugh Cole on Facebook
VP - Human Resources
Ted Harding
  Ted Harding LinkedIn Profile  Ted Harding Twitter Account  Ted Harding News  Ted Harding on Facebook
VP - Regulatory Affairs
Allison Nance
  Allison Nance LinkedIn Profile  Allison Nance Twitter Account  Allison Nance News  Allison Nance on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/23/2015: Ariste Medical venture capital transaction
Next: 4/24/2015: Simplus venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary